{"name":"Artery Therapeutics, Inc.","slug":"artery-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxPUjB4Qm4yaDBaWjdmMVphc1ZSOVJlVG5xUUZEMk5ndU1Oc2cxV3g2LWtIYmhvRFRkMUlYYnp0ekRrcmFTMmVmemN2SjlyeG1IWm9FeEpLcXBxZzIyNkJIY0VYbXktdWpXMjQ4aEJiRGYwVk5hNFZiWkcydDB2eTFWOXdsWXpMUFNFTk1yQmE0WXpyTjhaQ25KRkJ3dDVHdVdCUC1NOUVXbm9JZmNUZmN6bjF6X3F2Y2x4WWFUeXl3a3FTZ1hreF9HM2FlbWJjMmtTY2dKaERMci1BVE5TbDFtU3BQNU5iYzVodzhIeVBQeURyRGtlYzBiMUZLNklPS1R6TmFYekRWWXhyT3NiS05PeWRmTHFUWEthQmtmc3UwczFZaWZoXzNUVjdNVjROcTRKUEtPNmNzQVhkZjB6SHR4Vk5uM3lKN1NwNzBhRGxPOW80Zw?oc=5","date":"2026-04-07","type":"pipeline","source":"globenewswire.com","summary":"Inhibikase Therapeutics Announces Enrollment of First - globenewswire.com","headline":"Inhibikase Therapeutics Announces Enrollment of First","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQdk9YNFN5WWtmRUJvMktLOUhMV213MDdjRzJvVEFtYjlTS21OOS10UExRcm9BYkZ5aUNoMFZfd3ZldFNoT1NqSW5ZbnBKdjB5NzV5Q011Rjh6Q1ZucVlLYlBuQXR0NDdGSTBBNzczY1liamZaV0xLVjRVTzgwTHZSWk5CR2E1MHRfTGtGa19CTWVMbTlVTkw3aWJ2cl9zdk5EYmVXMlZrdi11endYMUt1RW5RdnZMR2JQNG5OTjR4YVNkZF9qRnJ1WXZ0YWY3NW1UajVXc0ota01MY1NGTXdGTElBeWd1b01tTHlfa0hxNEh3WmhESFFOTXk0bTQ2UQ?oc=5","date":"2026-02-05","type":"pipeline","source":"Barchart.com","summary":"Pulmonary Arterial Hypertension Pipeline Outlook: 55+ Companies Advancing Next-Generation Treatment Options, analyses DelveInsight - Barchart.com","headline":"Pulmonary Arterial Hypertension Pipeline Outlook: 55+ Companies Advancing Next-Generation Treatment Options, analyses De","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOWjd0c3RKbFhHV2hXWTU3UXpyaFRTbjVyY2pHdU1ic1BqY1ZITFVmV1djSV9tS1R6Y09fbjNMV1hYZWtjSzduTVV4cG5NQzRja2xWWE5TX1ZhOXF1YlQxcU9aVGlaX1Y0UWk1cmc4UUs0X0lIekpiTExWM1FxV3dGQS1ZZGpVd21rZUtiSUVjR2tZMTA0cDhwMHM3VGdoa245MzhiS0hOaUlaZEo2ZEZKVzRzVVNsaGQ4VUp2T2RQcw?oc=5","date":"2025-11-20","type":"trial","source":"Stock Titan","summary":"Inhibikase Therapeutics (Nasdaq: IKT) Plans Single Pivotal Phase 3 PAH Trial of IKT-001 - Stock Titan","headline":"Inhibikase Therapeutics (Nasdaq: IKT) Plans Single Pivotal Phase 3 PAH Trial of IKT-001","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPREtlVjVWVUp0cjZFWVQ2MU9wbjVSRmlIc29GWEMyLXhfVkpOeUc2cHFNYVc5OThvYmVMdjZaTlBYbEZCX2VDV2p0SGpvWHNJcXRHY0JWeXpYbDc2VFhZMHFldkJHbW9kcFBQWXNMemQ2aXg5bi1nSzhBY24tek8zVjlZVmZXRUJJMU1xbi1EX3REQWNRN2M2Y0pqUENVV0ZqV0h6Tkx0c3dnM3JjY2dQMFJ3T3hRRHFlZGJ5RWlqdURrOXl5b3h4TzhGOU55ZFRIUnFpTTRlMEl2S1ctajl1VEhjQ0dCOXVMcnNBcDg3aXpzMEk2LTE1Nk9JcHRGZkJuOEE?oc=5","date":"2025-11-20","type":"trial","source":"globenewswire.com","summary":"Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - globenewswire.com","headline":"Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNSUpOanNhMFQweksyc0dtcG9RUDlvTHZuczllWHRXTkxLZFpOckphOTdjd1g0ZFU2RUZKTUhQNXIxblJ2Z0UyLW1iS0ZUeWVEZ0JPeDNxOUJtN3dvTExMNVFFRjNhWWQ4SENPV3JnZXZJTloxTTBBd3hiWVhOMTltbC1nQWg5dm9ORnRQSnFIcXJPRGV0WGhPbw?oc=5","date":"2025-11-11","type":"pipeline","source":"Yahoo Finance","summary":"Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J&J, Sun Pharma, Lupin Pharma, GlaxoSmithKline, Bayer, United Therapeutics - Yaho","headline":"Pulmonary Arterial Hypertension Market Research Report 2025, Competitive Analysis of Gilead Sciences, Viatris, Sandoz, J","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5xcjVhM1E0ZzVrY1pBdExzZm50RmFEMTlneWhfcGtPZTdqZTBzZXkwdk1INDFKaktkZHN3OVRGdUt5S19sRExzd1A5ZGpDRGZTM01NblhhTEI5dDhCNjBpNkhjeGhHODRfWjZIODlWdlZlU2U3OTBjLVhR?oc=5","date":"2025-09-13","type":"trial","source":"Wiley","summary":"Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease - Wiley","headline":"Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxObnk1T1Y2TGdFTTVLYnE3cHJIbTdvRUlsYl94aE9ZZnZJajZWcmxteEc1MFJEcnR1NTRWUWVzR3dLN0hCY2Z1cUlocndsQ0JOMzFPNk84dFZRRE9vSWZqR3I3NDZSV0pSRU9TX0tEZjU2RDdoVnN4X0UwcDBGT0gwUlhtcmRteTNYejBDUW9VR2w0TTFuOUNsR2pJdUJBOXZTMi16ek13VEJtLTJfOGdYLWpuczNSdG9vazdiS1dWUHRVMUZrTDBJOWZLNXFqRjk0RUdqeUx3NnBPYkJ5ZHZUS2FTRUFJQlhkcXVRUk5BUE1Wak0zaEN5Z0hHdkVwdnVUTEE4VXdxTWlnMWxnbmNaYnJoSQ?oc=5","date":"2025-07-10","type":"trial","source":"Business Wire","summary":"First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease - Business Wire","headline":"First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Arter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOMTlnU0ZMWUVvM0VCUHl6UDZtTzJiTHphTHRrQVFRNTNTRFVZbVFOU0VFN2JmRVc5VzNQRnY0UTI4UEkxV1RRclQ1YThLZF9fQXE4WnBRN00tSWctMUFvcWhVX2I0UU9ldzh3NERPRkYzS0hlZUFxQUZWb1JUcnpDTDNRZjU1WG9ZR0F1U2VfQmtRT2JDTWRLZEkxUWtUNmpsZVk0Z0ZrVnJHenVwa2dCdHpidw?oc=5","date":"2025-06-10","type":"trial","source":"Fierce Pharma","summary":"Insmed's 'unprecedented' phase 2 PAH win sends stock soaring as the race to phase 3 kicks off - Fierce Pharma","headline":"Insmed's 'unprecedented' phase 2 PAH win sends stock soaring as the race to phase 3 kicks off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOWFpUVlk1RHUzSTlLdWtMRmMwREFCVllUTzlEd2hJdWFxOE9tYWdxM2RWckUzaXJQNkNGOUtKcjVxVk5teXZxT01ZLUtMZWJEaG9mQ0dOcFZZNnFNeE9JRU5KODZ1WEdoOFdac0JBTTd1WTVnbTBUQ09wV1Q4d1E1UWZHek9YT0d5WFpPamw4Z1ZFVkdHWmpaUDQ3Mjl4NFBJcWZkSFZLMllvNGlUQXBV?oc=5","date":"2025-06-10","type":"trial","source":"Investopedia","summary":"Insmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial Results - Investopedia","headline":"Insmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial Results","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPRU5oMk1KMVlMT1VvRG9oZ2tmc3FRQVBMOHpwa01VNjZDSWt3ekl4Rjc2SFZuVV9IRGlBcUlrYzlTenZmZm8yOHllUTVZdEVGSUdwNjJ2dTQ3a3Q1b20yMjlGWVVlc2hmZUQtUzh1alNoREluTHpRQ2ZjWFBBb3pVUTdIQ0xCSmJnOGFlbzNqSDB6Zw?oc=5","date":"2025-05-23","type":"pipeline","source":"Barron's","summary":"Heart Disease Could Be a Goner When These New Drugs Arrive - Barron's","headline":"Heart Disease Could Be a Goner When These New Drugs Arrive - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9UbEFsV3EwUGVxam02b3k0aUU2d19YZWtCS1NYV1ZFN1BITGdEcnNKTTBlT0NNOVF2clBUSmN2OWxaZGVsOUc5bTFNNTlITzQwSUlRaVAzMlFWM1ZMcUNqMEMxcUllaHhVNnZ1VXJjcmxrelk?oc=5","date":"2024-05-14","type":"pipeline","source":"American Heart Association Journals","summary":"Stepping Into the Future of Care for Patients With Peripheral Artery Disease - American Heart Association Journals","headline":"Stepping Into the Future of Care for Patients With Peripheral Artery Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNanlfOGtRY1NNalhuamVuY193c1ZGcVB0VzJISmgxVXZ1SkhnWWpad3dybDdYTE03WVdCNkI0cEd3NWI0dmdCNW05cjJyQ3JlQ1NrUXAzQ2JWOEduUmc2d3FLbmtTd0QzVTBXd3ZCU3dwN0h3WUtwWHFrMUVOLWtNZHUwd0huRFBIbWpDZHdDQ0M3Ync?oc=5","date":"2022-04-26","type":"pipeline","source":"National Institute on Aging (.gov)","summary":"NIA Small Business Showcase: Artery Therapeutics, Inc. - National Institute on Aging (.gov)","headline":"NIA Small Business Showcase: Artery Therapeutics, Inc. - National Institute on Aging (.gov)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}